TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE
Abstract
Transfusion associated graft versus host disease (TA-GVHD) results from engraftment of viable donor T-lymphocytes in recipient that can not recognize or destroy them. It is seen in immunocompromised patients and pre-mature neonates. It can also occur in immunocompetent individuals receiving blood from first-degree relatives. It has emerged as single most common cause of death resulting from transfusion. Patients with B-cell malignancies appear to be especially at risk. TA-GVHD is associated with 80-90% mortality. Death most commonly occurs due to infection or haemorrhage secondary to pancytopenia. It is therefore important to prevent its occurrence. Prevention can be achieved either by complete removal of T-lymphocytes from donors blood or by abolishing their proliferating potentials. Available methods of leuko-depletion are not effective in preventing TA-GVHD. Only effective way is to inactivate T-lymhocytes. This can be achieved by irradiating blood product with gamma or X-ray irradiation. The concerns about malignant transformation of cells or reactivation of intracellular viruses have not been proved so far. Newer technologies for T-cell inactivation, which are not based on irradiation, are currently under trial.Key words: Transfusion hazards, TA-GVHD, Graft versus Host Disease, Blood product irradiation, Transfusion to immunocompromised, Transfusion from first degree relativesReferences
Brubaker DB. Human post-transfusion graft versus host disease. Vox Sang 1983; 45:401-420
Thaler M, Shamiss A, Orgad S, Huszar M, Nussinivitch N, Meisel S, et al: The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Eng J Med 1989; 321:25-8.
British Blood Transfusion Society (2002). SHOT Annual Report 2000-2001.
Ohto H, Anderson KC. Survey of transfusion associated graft-versus-host disease in immunoco-mpetent recipients. Trans Med Rev 1996;10:31-43.
Ministry of Health, Pakistan (2003) National Blood Policy and Strategic Framework Document: Executive Summary.
Billingham R. The biology of graft-versus-host reactions. Harvey Lectures 1966-67; 62: 21-78.
Ferrara JL, Krenger W. Graft-versus-host disease: The influence of type 1 and type 2 T cell cytokines. Trans Med Rev 1998;12:1-17.
Kunstmann E, Bocker T, Roewer L, Sauer H, Mempel W, Epplen JT. Diagnosis of transfusion-associated graft-versus-host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992;32:766-70.
Korngold R. Biology of graft-versus-host disease. American Journal of Paediatric Haematology Oncology 1993;15:18-37.
NBTS/NIBSC (1993) Guidelines for the Transfusion Service. HMSO, United Kingdom.
Gorlin J, Mintz P. Transfusion-associated graft-versus-host disease. In Mintz P (ed): Transfusion Therapy: Clinical Principles and Practice. Bethesda, Md, AABB Press, 1999; pp 341-57.
BCSH Blood Transfusion Task Force (Chairman D. Voak). Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine 1996; 6:261-71.
Fast LD, DiLeone G, Edson CM, Purmal A. PEN 110 treatment functionally inactivates the PBMNCs present in RBC units: Comparison to the effects of exposure to g irradiation. Transfusion 2002; 42: 1318-25.
Lazo A, Tassello J, Jayarama J, Ohagen A, Gibaja V, Kramer E et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN 110 chemistry. Vox Sang 2002; 83: 313-23.
Zavizion B, Serebryanik D, Serebryanik I, Chapman J, Purmal A. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion 2003;43:135-42.
Downloads
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.